AR130952A1 - Formulación oral de un derivado de n-piridinil acetamida - Google Patents

Formulación oral de un derivado de n-piridinil acetamida

Info

Publication number
AR130952A1
AR130952A1 ARP230102947A ARP230102947A AR130952A1 AR 130952 A1 AR130952 A1 AR 130952A1 AR P230102947 A ARP230102947 A AR P230102947A AR P230102947 A ARP230102947 A AR P230102947A AR 130952 A1 AR130952 A1 AR 130952A1
Authority
AR
Argentina
Prior art keywords
oral formulation
acetamide derivative
pyridyl
subject
lung disease
Prior art date
Application number
ARP230102947A
Other languages
English (en)
Inventor
Caroline Ann Owen
Susanne Prothon
Michael Lee Williams
Nicola Ferrari
Hkan Wikstrm
Veronika Sjstrand
Rebecca Fransson
Alexandra Pavlovna Chukharkina
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR130952A1 publication Critical patent/AR130952A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Reivindicación 1: Un método para tratar la enfermedad pulmonar intersticial en un sujeto que lo necesite, que comprende administrar por vía oral al sujeto 2-[4-(2-metil-4-piridil)pirrolo[3,2-c]piridin-1-il]-N-(5-pirazin-2-il-2-piridil)acetamida (AZD5055): de fórmula (1) en una dosis de entre 5 y 35 mg al día. Reivindicación 13: El método según una cualquiera de las reivindicaciones 1 a 12, que comprende adicionalmente la administración separada, secuencial o simultánea de un inhibidor de la bomba de protones o una sal farmacéuticamente aceptable del mismo. Reivindicación 14: El método según la reivindicación 13, en donde el inhibidor de la bomba de protones es rabeprazol. Reivindicación 16: El método según una cualquiera de las reivindicaciones 1 a 15, en donde la enfermedad pulmonar intersticial es fibrosis pulmonar idiopática.
ARP230102947A 2022-11-04 2023-11-03 Formulación oral de un derivado de n-piridinil acetamida AR130952A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202263382311P 2022-11-04 2022-11-04

Publications (1)

Publication Number Publication Date
AR130952A1 true AR130952A1 (es) 2025-02-05

Family

ID=88689993

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP230102947A AR130952A1 (es) 2022-11-04 2023-11-03 Formulación oral de un derivado de n-piridinil acetamida

Country Status (14)

Country Link
JP (1) JP2025536575A (es)
KR (1) KR20250099240A (es)
CN (1) CN120187430A (es)
AR (1) AR130952A1 (es)
AU (1) AU2023374727A1 (es)
CL (1) CL2025001306A1 (es)
CO (1) CO2025007400A2 (es)
CR (1) CR20250229A (es)
DO (1) DOP2025000103A (es)
IL (1) IL320576A (es)
MX (1) MX2025005174A (es)
PE (1) PE20251575A1 (es)
TW (1) TW202434248A (es)
WO (1) WO2024094844A1 (es)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017007218B1 (pt) 2014-10-08 2023-10-10 Redx Pharma Plc Derivados de n-piridil acetamida como inibidores da via de sinalização de wnt, formulações farmacêuticas compreendendo os mesmos e seus usos

Also Published As

Publication number Publication date
TW202434248A (zh) 2024-09-01
CR20250229A (es) 2025-07-11
DOP2025000103A (es) 2025-06-15
CL2025001306A1 (es) 2025-08-01
WO2024094844A1 (en) 2024-05-10
KR20250099240A (ko) 2025-07-01
PE20251575A1 (es) 2025-06-12
CN120187430A (zh) 2025-06-20
JP2025536575A (ja) 2025-11-07
CO2025007400A2 (es) 2025-06-16
MX2025005174A (es) 2025-06-02
AU2023374727A1 (en) 2025-06-19
IL320576A (en) 2025-07-01

Similar Documents

Publication Publication Date Title
ES2518418T3 (es) Composiciones de vasoconstricción y métodos de uso
US11786496B2 (en) Composition and methods for treating intestinal hyperpermeability
HUP0204079A2 (hu) Szedatív hatástól mentes antihisztaminok és leukotrién hatást befolyásoló anyagok új kombinációja orrnyálkahártya-gyulladás, vagy kötőhártya-gyulladás kezelésére
AU2004233587B2 (en) Use of a topical medicament comprising Riluzole
JP5780430B2 (ja) 勃起不全の処置用のPDE5阻害剤と組み合わせたsGC刺激剤またはsGC活性化剤
KR102689822B1 (ko) 코로나바이러스의 치료 방법
CA2304162A1 (en) Use of combinations comprising non-sedating antihistamines and alpha-adrenergic drugs for the topical treatment of rhinitis/conjunctivitis and cold, cold-like and/or flu symptoms
CN113893239A (zh) 用于治疗肠渗透性过高的酪氨酸羟化酶抑制剂
JP2024102113A (ja) 毛髪の成長を刺激するためのアルファ-ケトブチレート、アルファ-ケトグルタレート、および2-ヒドロキシブチレート
ES2551752T3 (es) Composiciones de bepotastina
US9408831B2 (en) Methods for treating respiratory viral infection
CL2024001530A1 (es) Nuevas combinaciones terapéuticas para el tratamiento de enfermedades pulmonares intersticiales fibrosantes progresivas
CL2024003616A1 (es) Composición farmacéutica oral y uso para la terapia de enfermedades pulmonares intersticiales fibrosantes progresivas.
JP2014224143A (ja) 他の薬剤と組合せた(r,r)−ホルモテロール
KR20070048199A (ko) 바이러스의 억제, 파괴 및/또는 불활성화를 위한 방법 및조성물
TW202106690A (zh) 皮膚型紅斑狼瘡之治療
UA123780C2 (uk) Лікування екземи кистей
CN111821299A (zh) 噻吩衍生物用于治疗免疫球蛋白E(IgE)介导的疾病的应用
CN104324018A (zh) 广藿香醇在制备男性性功能障碍药物或保健品中的应用
JP2008542290A (ja) 皮膚狼瘡の治療又は予防のための4−[(シクロプロパンカルボニルアミノ)メチル]−2−(2,6−ジオキソピペリジン−3−イル)イソインドール−1,3−ジオンの使用方法及び組成物
JP5800485B2 (ja) 鼻汁分泌抑制用組成物
JP2017505350A (ja) 硫黄含有部分を含む糖誘導体ならびにその作製方法およびmps iiicの処置のためのその使用方法
PE20251575A1 (es) Formulacion oral de derivado de n-piridinilacetamida para tratar la enfermedad pulmonar intersticial
AR118056A2 (es) Formulaciones de inhibidor de histona desacetilasa en combinación con bendamustina y uso de las mismas
CN105873611A (zh) 利用pde4调节剂治疗病毒性疾病的组合物和方法